Try our Advanced Search for more refined results
Life Sciences
-
March 17, 2026
Fenwick Healthcare Regulatory Atty Rejoins Latham In LA
Latham & Watkins LLP is boosting its healthcare team, announcing Monday it is welcoming back a Fenwick & West LLP healthcare regulatory expert as a partner in its Los Angeles office.
-
March 16, 2026
1st Circ. Affirms Block Of Trump's 'Unprecedented' Aid Freeze
The First Circuit on Monday mostly upheld a lower court's order blocking the Trump administration from enacting a "sweeping and unprecedented categorical 'freeze' of federal financial assistance," ruling that the states involved in the suit will likely successfully show that the federal government acted arbitrarily and capriciously.
-
March 16, 2026
Judge Tosses Kaiser Whistleblowers' Claims After $556M Deal
A California federal court on Monday officially dismissed False Claims Act lawsuits from the federal government and three people alleging that Kaiser Permanente affiliates engaged in Medicare fraud, on the heels of Kaiser's $556 million settlement reached in January.
-
March 16, 2026
Lannett Investors Seek Final OK Of $5.8M Price-Fix Probe Suit
Former executives of pharmaceutical company Lannett Inc. and a class of investors have asked a Pennsylvania federal court to grant final approval to their $5.8 million deal to end claims the company and its leadership misled about Lannett's links to allegations of industrywide price-fixing in the market for generic drugs.
-
March 16, 2026
J&J's Lack Of Malice Gets $966M Talc Verdict Cut To $16M
A California state judge slashed $950 million in punitive damages from a $966 million jury verdict against Johnson & Johnson on Friday in a lawsuit involving an 88-year-old woman who died of mesothelioma, saying the estate's counsel failed to sufficiently show the pharmaceutical giant acted maliciously.
-
March 16, 2026
Medtronic Seeks To Ax 'Extreme Outlier' $382M Antitrust Loss
Medtronic has urged a California federal judge to scrap its nearly $382 million trial loss to rival Applied Medical over Medtronic's bundling practices that a jury found suppressed competition for advanced bipolar devices, arguing the verdict is an "extreme outlier" in antitrust law that can't survive.
-
March 16, 2026
Amgen And Sanofi End Repatha IP Fight Heard By Justices
Amgen Inc. and Sanofi have settled patent litigation over competing cholesterol drugs Repatha and Praluent, more than two years after they dueled at the U.S. Supreme Court, Sanofi confirmed Monday.
-
March 16, 2026
Italy's Amplifon Buying Danish Hearing Device Biz For $2.6B
Italy's Amplifon said Monday it has agreed to acquire the hearing device business of Denmark's GN Store Nord in a deal valuing the unit at about €2.3 billion ($2.6 billion), in a move aimed at creating a vertically integrated global leader in audiology.
-
March 16, 2026
HHS' Childhood Vaccine Policy Changes Put On Ice
A Massachusetts federal judge on Monday blocked the Trump administration's modified childhood vaccine schedule and put all decisions made by Health Secretary Robert F. Kennedy Jr.'s federal vaccine policy committee on hold, finding they veered sharply from normal procedure and likely violated the law.
-
March 16, 2026
Catching Up With Delaware's Chancery Court
The Delaware Chancery Court's docket last week featured disputes including an $83.75 million settlement tied to a renewable energy merger, fraud claims in a fertilizer company acquisition and a developer's fight for control of a major Philadelphia redevelopment project.
-
March 13, 2026
AIG Policy Excludes $150M Pollution Coverage, 7th Circ. Finds
A Seventh Circuit panel on Friday ruled an AIG unit has no duty to cover $150 million in legal costs for Sterigenics and its former parent company following input from the Illinois Supreme Court on how to apply a pollution exclusion in the relevant policy.
-
March 13, 2026
Maryland Bros. Get Prison For HIV Drug Fraud Scheme
A Florida federal judge on Friday sentenced two Maryland brothers to prison for their roles in a fraudulent medication scheme that involved selling misbranded HIV drugs with fake tracing documents to pharmacies and patients.
-
March 13, 2026
She Has A Point: Finnegan's Cora Holt
Cora Holt, a partner at Finnegan Henderson Farabow Garrett & Dunner LLP in Washington, D.C., has a "do your job" attitude and "getting the stuff done" approach to litigation that earned plaudits from Kassie Helm, co-chair of Dechert LLP, who praised Holt for her work as part of a Law360 series celebrating women litigators.
-
March 13, 2026
Neuropsych Drugmaker Wants Out Of Investors' IPO Data Suit
Neuropsychiatric drugmaker Neumora Therapeutics Inc. seeks to shed investor claims it mischaracterized certain clinical study data ahead of its September 2023 initial public offering, arguing that the trading price decline cited in the complaint was tied to results from a different study that occurred after the IPO.
-
March 13, 2026
4th Circ. Brings Back Allergan Medicaid Overcharging Suit
A split Fourth Circuit panel on Friday revived a whistleblower suit accusing an Allergan Sales LLC predecessor of overcharging Medicaid by more than $680 million, saying the whistleblower plausibly alleged the company knowingly improperly aggregated discounts into "best prices" for drugs.
-
March 13, 2026
Sandoz Appealing Ruling Over Amgen's Enbrel Biosimilar
Sandoz Inc. is appealing after a Virginia federal court ruled it should have brought claims accusing Amgen of blocking competition for the Enbrel biosimilar in a previous patent dispute, according to a Friday notice.
-
March 13, 2026
Kroger Agrees To Pay $17M In Drug Copay Inflation Case
Kroger pharmacy customers reached a $17 million settlement with the grocer resolving allegations that it inflated their copays for insured prescriptions, according to a motion for preliminary approval of the deal filed in Ohio federal court.
-
March 13, 2026
Life Sciences Partner Hiring Up Amid Regulatory Scrutiny
Large law firms' partner additions in life sciences rose slightly across five geographic markets between 2024 and 2025, with several factors including increased regulatory scrutiny driving new additions, according to an analysis by intelligence platform Macrae+.
-
March 13, 2026
J&J Unit Says Ex-Director Misappropriated Trade Secrets
A Johnson & Johnson subsidiary has accused a former associate director of downloading over 7,000 files worth of confidential information prior to her resignation and using it to start her own competing company.
-
March 12, 2026
Orthopedics Co. Investors See Merger Claims Trimmed
Orthofix Medical Inc. must face claims that it failed to tell investors that a company it was merging with recently settled class action discrimination allegations, but will not have to face some securities fraud allegations, a Texas federal judge has ruled.
-
March 12, 2026
DC Circ. Spends Hours Debating 'Same' Generic Label Reqs
The D.C. Circuit spent more than three hours Thursday going round with Vanda Pharmaceuticals and the U.S. Food and Drug Administration about whether the label for a generic sleep-wake disorder medication is "the same" as the branded one because it doesn't include Braille.
-
March 12, 2026
Tom's Toothpaste Trims Class Action Over Lead Levels
Tom's of Maine can't beat back proposed class claims it allowed heavy metals to taint its children's toothpaste, a New York federal judge ruled Wednesday, finding that the parent behind the suit adequately claimed the company falsely marketed the products as "safe" and "healthy."
-
March 12, 2026
IP Notebook: TM Use Fight, Popeye, Kurt Cobain
This edition of emerging copyright and trademark cases and trends looks at an appeal before the U.S. Supreme Court that questions the definition of trademark "use in commerce" under the Lanham Act and a battle over the use of "Popeye" as a trademark.
-
March 12, 2026
Embryo Loss Suits Need 'Serious' Edits, Judge Told
Two complaints against fertility products maker CooperSurgical Inc. require "serious" amendments to clarify the nature of the claims that a defective culture medium caused embryo losses for in vitro fertilization patients, the company told a Connecticut federal judge Thursday.
-
March 12, 2026
US Chamber Report Warns Of Risks To IP Protection
While the U.S. has ranked at the top of the U.S. Chamber of Commerce's list measuring how countries worldwide are enforcing intellectual property laws, the group said problems with free trade agreements and efforts to reduce pharmaceutical prices could cause problems on the horizon domestically.
Expert Analysis
-
How 11th Circ.'s Qui Tam Review Could Affect FCA Litigation
On Dec. 12, the Eleventh Circuit will hear arguments in U.S. ex rel. Zafirov v. Florida Medical Associates, setting the stage for a decision that could drastically reduce enforcement under the False Claims Act, and presenting an opportunity to seek U.S. Supreme Court review of the act's whistleblower provisions, say attorneys at Epstein Becker.
-
Series
The Biz Court Digest: Welcome To Miami
After nearly 20 years in operation, the Miami Complex Business Litigation Division is a pioneer upon which other jurisdictions in the state have been modeled, adopting many innovations to keep its cases running more efficiently and staffing experienced judges who are accustomed to hearing business disputes, say attorneys at King & Spalding.
-
Identifying And Resolving Conflicts Among Class Members
As the Fifth Circuit's recent decision in Nova Scotia Health Employees' Pension Plan v. McDermott International illustrates, intraclass conflicts can determine the fate of a class action — and such conflicts can be surprisingly difficult to identify, says Andrew Faisman, a clerk at the U.S. District Court for the Southern District of New York.
-
Adapting To A Plaintiff-Side Mindset For Patent Monetization
A recent decrease in risk for patent owners at the U.S. Patent and Trademark Office, combined with increased corporate interest in monetizing patent assets, creates an attractive case for evaluating patents from a plaintiff-side mindset, but in-house counsel transitioning from a defense-side mindset to a plaintiff-side mindset should study certain considerations, says Kate Tellez at Steptoe.
-
AI Evidence Rule Tweaks Encourage Judicial Guardrails
Recent additions to a committee note on proposed Rule of Evidence 707 — governing evidence generated by artificial intelligence — seek to mitigate potential dangers that may arise once machine outputs are introduced at trial, encouraging judges to perform critical gatekeeping functions, say attorneys at Lankler Siffert & Wohl.
-
Series
The Law Firm Merger Diaries: Getting The Message Across
Communications and brand strategy during a law firm merger represent a crucial thread that runs through every stage of a combination and should include clear messaging, leverage modern marketing tools and embrace the chance to evolve, says Ashley Horne at Womble Bond.
-
Opinion
Horizontal Stare Decisis Should Not Be Casually Discarded
Eliminating the so-called law of the circuit doctrine — as recently proposed by a Fifth Circuit judge, echoing Justice Neil Gorsuch’s concurrence in Loper Bright — would undermine public confidence in the judiciary’s independence and create costly uncertainty for litigants, says Lawrence Bluestone at Genova Burns.
-
10 Commandments For Agentic AI Tools In The Legal Industry
Though agentic artificial intelligence has demonstrated significant promise for optimizing legal work, it presents numerous risks, so specific ethical obligations should be built into the knowledge base of every agentic AI tool used in the legal industry, says Steven Cordero at Akerman LLP.
-
Fed. Circ. In Oct.: Spotlight On Wording Beyond Patent Claims
The Federal Circuit's recent decision in Barrette Outdoor Living v. Fortress Iron provides useful guidance on how patent prosecutors should avoid language that triggers specification disclaimer and prosecution disclaimer, doctrines that may be used to narrow the scope of patent infringement claims, say attorneys at Knobbe Martens.
-
New Drug Ad Regs Could Lead To A Less Informed Public
A federal push to mandate full safety warnings in pharmaceutical advertising could make drug ads less appealing for companies to air, which in turn could negatively affect consumers' health decisions by removing an accessible information source, say Punam Keller at Dartmouth College and Ceren Canal Aruoba at Berkeley Research Group.
-
Series
Preaching Makes Me A Better Lawyer
Becoming a Gospel preacher has enhanced my success as a trial lawyer by teaching me the importance of credibility, relatability, persuasiveness and thorough preparation for my congregants, the same skills needed with judges and juries in the courtroom, says Reginald Harris at Stinson.
-
A Look At Middlemen Fees In 340B Drug Discount Program
A U.S. Senate committee's recent hearing on the Section 340B drug discount program, along with statistical analysis of payment amounts, contribute to a growing consensus that middlemen fees are too high, say William Sarraille at the University of Maryland, and Shanyue Zeng and Rory Martin at IQVIA.
-
How Large Patent Damages Awards Actually Play Out
Most large verdicts in patent infringement cases are often overturned or reduced on appeal, implying that the Federal Circuit is serving its intended purpose of correcting outlier outcomes, and that the figures that catch headlines and dominate policy debates may misrepresent economic realities, says Bowman Heiden at Berkeley School of Law.
-
Series
Law School's Missed Lessons: Practicing Client-Led Litigation
New litigators can better help their corporate clients achieve their overall objectives when they move beyond simply fighting for legal victory to a client-led approach that resolves the legal dispute while balancing the company's competing out-of-court priorities, says Chelsea Ireland at Cohen Ziffer.
-
Navigating 2025's Post-Grant Proceeding Shakeups
Extensive changes to the U.S. Patent Trial and Appeal Board's post-grant proceedings this year, including the new settled expectations factor and revitalization of Fintiv factors, require petitioners and patent owners alike to be mindful when selecting patents to assert and challenge, say attorneys at Quinn Emanuel.